Diabetes
Refine Search
Pharmaceutical
China's type 2 diabetes market will increase from a value of $1.4 billion in 2009 to $2.5 billion in 2014, according to an emerging markets report from advisory firm Decision Resources, which sees attributes this growth to an increasing drug-treated population, expanding medical insurance coverage and the launch and adoption of new drugs in the market. 3 December 2010
Pharmaceutical
More than 50% of Americans could have diabetes or pre-diabetes by 2020 at a cost of $3,350 billion over the next decade if current trends continue, according to new analysis by UnitedHealth Group's Center for Health Reform & Modernization, but there are also practical solutions for slowing the trend. 25 November 2010
Pharmaceutical
The type 2 diabetes market in Mexico will grow to $1.22 billion in 2014, forecasts research and advisory firm Decision Resources. Drivers of this growth include increasing prevalent population, expanding medical insurance coverage as well as the launch and use of new drugs in the market. 16 November 2010
Pharmaceutical
Scientists from USA-based specialty pharmaceutical firm Biodel (Nasdaq: BIOD) reported new findings from the company's Linjeta, (insulin glargine), "smart" basal insulin and stabilized glucagon development programs in poster presentations at the Tenth Annual Diabetes Technology Meeting in Bethesda, Maryland, USA, last Friday. 15 November 2010
Pharmaceutical
It is business as usual for Alkermes (Nasdaq: ALKS) as it tries to bounce back from the Bydureon (exenatide extended-release for injectable suspension) disappointment, when the US Food and Drug Administration issued a complete response letter relating to the drug, which is under development with US drug major Eli Lilly (NYSE: LLY) and Amylin Pharmaceuticals (Nasdaq: AMLN) requesting additional information (The Pharma Letter October 20). 15 November 2010
Pharmaceutical
With the incidence of diabetes escalating across the Middle East and Northern Africa (MENA) region, new research finds a worrying lack of awareness about the causes and risk factors that the disease poses for patients. 15 November 2010
Pharmaceutical
Recent research results demonstrate that a new treatment approach to diabetes, GLP-1 analogues, not only helps to lower blood glucose levels, but has the added benefit of reducing body mass index (BMI) and waist circumference, said Danish insulin giant Novo Nordisk (NVO. N), the maker of Victoza (liraglutide). 9 November 2010
Pharmaceutical
The US Food and Drug Administration approved Kombiglyze XR, a drug resulting from a 2007 collaboration between drug majors Anglo-Swedish firm AstraZeneca (LSE: AZN) and the USA's Bristol-Myers Squibb (NYSE: BMY), for the treatment of type 2 diabetes in adults. 8 November 2010
Pharmaceutical
In a speech to the Cleveland Clinic Medical Innovation Summit yesterday, John Lechleiter, chairman, president and chief executive of US drug major Eli Lilly (NYSE: LLY) described the "paradox of progress" against diabetes, noting that "for all our progress in treating diabetes, our ultimate goal seems as far away as ever." He called for a new "wave of invention" to combat the disease. 4 November 2010
Pharmaceutical
Shares of US specialty pharmaceutical firm Biodel (Nasdaq: BIOD) plunged 52% to $1.74 in early trading yesterday, after the US regulator said it could not approve the firm's lead drug candidate without considerable further late-stage clinical data. 2 November 2010
Pharmaceutical
Danish insulin and diabetes drug major Novo Nordisk (NVO.N) reported results for the first nine months of 2010, showing that sales were 19.47 billion Danish kroner ($3.63 billion), up 17% in kroner terms and 12% higher measured in local currencies, driven primarily by better-than-expected sales of its new diabetes drug Victoza (liraglutide), Levemir (insulin detemir) and NovoRapid (insulin aspart). All regions contributed to growth measured in local currencies. 27 October 2010
Pharmaceutical
Amylin Pharmaceuticals (Nasdaq: AMLN) received a disappointment yesterday, when the increasingly risk-averse US Food and Drug Administration issued a complete response letter regarding the firm's New Drug Application for its type 2 diabetes drug candidate Bydureon (exenatide extended-release for injectable suspension), calling for additional clinical data. 20 October 2010
Biotechnology
Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an agreement with global drugs behemoth Pfizer (NYSE: PFE) for the worldwide commercialization of Biocon's biosimilar versions of insulin and insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Biocon's shares rose 8.7% to 438.30 rupees in Mumbai trading early yesterday, having leapt as much as 17%. 19 October 2010
Pharmaceutical
In a third accord with academia this year, Sanofi-Aventis (Euronext: SAN) this morning announced a research collaboration with the USA's Harvard University. The goal of this is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard and the French drug major. Financial terms of the accord were not disclosed. 19 October 2010
Pharmaceutical
In an article published on October 11, titled Merck & Co's Banyu unit warned about paying Japanese doctors for attending conferences, it was wrongly stated that Banyu had paid out 1 billion yen to 325 doctors who attended medical seminars organized by the company with regard to its diabetes drug Januvia (sitagliptin). The figure should have been 10 million yen ($120,000). 19 October 2010
Pharmaceutical
US drug major Bristol-Myers Squibb's (NYSE: BMY) R&D pipeline received a boost when its type 2 diabetes candidate, dapagliflozin, fared well in a late-stage multicenter, active-controlled, randomized, parallel-group, double-blind, study (n=814), according to a report last Friday from Zacks Equity Research. The patients enrolled in the study were above 18 years of age and had responded unsatisfactorily to treatment by metformin alone. 18 October 2010
Pharmaceutical
Japanese drugmaker Banyu, a wholly-owned subsidiary of US drugs giant Merck & Co (NYSE: MRK), has been warned about making payments of around 10 million yen ($120,000) to 325 doctors who attended medical seminars organized by the company with regard to its diabetes drug Januvia (sitagliptin), by the Kotorikyo, Japan's Fair Trade Council of the Ethical Pharmaceuticals Drugs Marketing Industry. 11 October 2010
Pharmaceutical
Following the European Medicines Agency (EMEA) decision last month to suspend the marketing authorization for UK drug giant GlaxoSmithKline's (LSE: GSK) type 2 diabetes drug Avandia (rosiglitazone), and the US Food and Drug Administration imposing additional restrictions on the drug due to its cardiovascular side effects (The Pharma Letter September 24), health care research group Datamonitor has surveyed a group of US physicians who currently prescribe Avandia products, to find out what effect the FDA restrictions on the product's sales would have on their prescribing habits. 7 October 2010
Pharmaceutical
With around 51 million diabetic patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of insulin and non-insulin anti-diabetics reached $424 million, according to the findings of a news report added to the offering of Research and Markets. Although, this represents just a fraction of the global sales, the authors expect this market to surge in the future. 6 October 2010
Pharmaceutical
Danish insulin giant and diabetes drug major Novo Nordisk (NVO.N) yesterday announced a $73 million expansion of its Clayton, North Carolina, USA, manufacturing facility to accommodate increased production capacity for the company's insulin delivery devices. 5 October 2010
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze